Last updated: July 20, 2026
Neurelis, Inc. v. Padagis LLC, case number 1:24-cv-00562, is a 2024 patent infringement dispute brought by Neurelis against Padagis. The record required to produce a complete and accurate litigation summary (asserted patents, claim numbers, court holdings, procedural posture milestones, and outcomes) is not available in the provided input, so a full, case-grade analysis cannot be generated.
What is Neurelis, Inc. v. Padagis LLC (1:24-cv-00562) about?
A substantive litigation summary requires the complaint’s pleaded facts and the asserted patent set. Without the complaint and docket detail, the following cannot be stated accurately: asserted patent numbers, alleged products or acts of infringement, the theories (direct/induced/contributory), and the specific causes of action (infringement, declaratory judgment, willful infringement, injunctive relief).
Which patents are asserted in Neurelis v. Padagis (1:24-cv-00562)?
A complete “what patents protect” mapping must list:
- patent numbers and publication numbers
- filing/priority chain
- asserted independent and dependent claims
- expiration and regulatory exclusivity ties
No patent identifiers are included in the provided input, so the asserted estate cannot be enumerated.
What claims are at issue and how do Neurelis and Padagis frame infringement?
Case-grade claim analysis requires, at minimum:
- Neurelis’s infringement contentions (claim chart basis, element-by-element mapping)
- Padagis’s defenses (non-infringement, invalidity grounds, prosecution history estoppel, indefiniteness, written description/enablement)
- any Markman-order status
Those details are not present, so infringement and invalidity contentions cannot be summarized without risking factual inaccuracy.
What procedural stage is the case in (filing date, motions, claim construction, trial schedule)?
An actionable timeline depends on docket events, including:
- complaint filing and service
- answer or Rule 12 motions
- any Rule 16 scheduling conference
- Markman/claim construction deadlines
- dispositive motion practice
- injunction motion activity
- settlement or dismissal entries
No docket timeline is provided, so current posture and near-term litigation risk cannot be stated.
What relief is Neurelis seeking in Neurelis v. Padagis?
A litigation summary should quantify sought relief, including:
- permanent injunction scope (product, method, or manufacturing)
- preliminary injunction requests and likelihood analysis
- damages theory (reasonable royalty vs. lost profits)
- enhanced damages and attorneys’ fees (willfulness)
The complaint’s requested relief is not included in the provided input.
Has there been a settlement, dismissal, or consent judgment in 1:24-cv-00562?
Settlement and case disposition can materially change commercial exposure and licensing leverage. Determining whether the case ended in:
- dismissal with prejudice
- covenant-not-to-sue
- settlement agreement
- consent judgment
requires docket outcomes that are not present in the provided input.
How could the asserted Neurelis IP affect generic or competitor launch risk for Padagis?
Linking litigation to launch risk requires:
- whether Padagis is making, using, selling, offering to sell, or importing the accused product
- whether the case is tied to FDA approvals (ANDA/BLA) or non-FDA commercial activity
- any Paragraph IV or Orange Book alignment (if applicable)
None of those cross-links can be verified from the provided input.
How strong is the likely patent estate underlying the dispute?
Strength analysis normally includes:
- claim breadth vs. prior art
- prosecution history and litigated limitations
- common invalidity theories (102/103, 112)
- patent family size and continuation strategy
- litigation history of the same family
No asserted patents or prosecution facts are available in the provided input.
What manufacturing or formulation design-arounds are typically relevant in Neurelis-style cases?
A practical design-around analysis needs the claim elements and the accused product attributes (composition, dosing form, process parameters). Without the claim set and product description, this cannot be performed reliably.
How does Neurelis v. Padagis compare with other Neurelis patent disputes?
Comparative analysis requires other docket numbers, overlapping patents, and adjudicated outcomes. No comparator case list is provided.
Key Takeaways
- Case identified: Neurelis, Inc. v. Padagis LLC, 1:24-cv-00562.
- But: No asserted patent numbers, claim scope, procedural milestones, or disposition details are provided, so a complete litigation summary and IP risk analysis cannot be produced without introducing inaccuracies.
FAQs
- What patents are typically asserted in Neurelis product-related litigation, and how do you verify them?
- How do Neurelis cases usually litigate claim scope through Markman hearings?
- What are the most common defenses in Neurelis v. competitor disputes (non-infringement, invalidity, 35 U.S.C. § 112)?
- How can you map a patent infringement case to FDA approval timelines for launch risk?
- What settlement terms are most common in Hatch-Waxman-related patent cases involving branded neurology assets?
References
No sources were provided in the prompt, and no case docket or complaint text is available in the input to cite.
